首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Analysis of the Pharmacokinetic Interaction between Cephalexin and Quinapril by a Nonlinear Mixed-Effect Model
【2h】

Analysis of the Pharmacokinetic Interaction between Cephalexin and Quinapril by a Nonlinear Mixed-Effect Model

机译:非线性混合效应模型分析头孢氨苄与奎那普利之间的药代动力学相互作用

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Oligopeptidic drugs such as β-lactams and angiotensin-converting enzyme inhibitors share the same carriers in humans and animals, which results in possible pharmacokinetic interactions. To model such interactions, the effects of quinapril on cephalexin pharmacokinetics were investigated in rats. Blood cephalexin concentrations were measured by liquid chromatography, and the data were analyzed by a noncompartmental method and by fitting a bicompartmental model by a nonlinear mixed-effect modeling approach. Five groups of eight rats were examined. In the first three groups, cephalexin elimination kinetics after intra-arterial administration alone or in combination with quinapril given by the parenteral or the oral route were studied, and the occurrence of a pharmacokinetic interaction was not revealed. The absence of an effect of quinapril on cephalexin elimination after parenteral administration might be explained either by the higher affinity of cephalexin for the renal anionic transport system than that of quinapril or by the much higher concentrations of cephalexin than those of quinapril. In the last two groups, cephalexin was administered by the oral route alone or in combination with quinapril. The mean area under the concentration-time curve (AUC) for cephalexin was increased by ca. 30% by coadministration of quinapril (40.1 versus 31.4 mg · h/liter; P = 0.04). The mean elimination clearance of cephalexin was significantly decreased by quinapril, from 0.81 to 0.64 liter/h/kg of body weight (P < 0.05), probably by competitive inhibition of cephalexin secretion at the tubular level. The mean absorption rate constant of cephalexin was significantly lowered by quinapril (from 0.249 to 0.177 h−1; P < 0.01), without modification of the extent of absorption (89%). This pharmacokinetic interaction could be explained by competitive inhibition of cephalexin active transport by quinapril at the intestinal level.
机译:诸如β-内酰胺和血管紧张素转化酶抑制剂之类的寡肽药物在人和动物中共享相同的载体,这可能导致药代动力学相互作用。为了建立这种相互作用的模型,研究了奎纳普利对大鼠头孢氨苄药代动力学的影响。通过液相色谱法测定血液中的头孢氨苄浓度,并通过非房室方法分析数据并通过非线性混合效应建模方法拟合双室模型。检查五组,每组八只大鼠。在前三组中,研究了单独或与肠胃外或口服途径合用奎那普利经动脉内给药后的头孢氨苄清除动力学,但未发现药代动力学相互作用的发生。肠胃外给药后奎纳普利对消除头孢氨苄没有作用,可能是因为头孢氨苄对肾脏阴离子转运系统的亲和力比奎那普利高,或者头孢氨苄的浓度比奎那普利高得多。在最后两组中,头孢氨苄通过口服途径单独或与奎那普利合用。头孢氨苄在浓度-时间曲线(AUC)下的平均面积增加了约。奎那普利的30%共同给药(40.1对31.4 mg·h /升; P = 0.04)。奎尼普利可显着降低头孢氨苄的平均清除清除率,从0.81降至0.64升/小时/千克体重(P <0.05),这可能是由于在肾小管水平竞争性抑制了头孢氨苄的分泌。喹那普利使头孢氨苄的平均吸收速率常数显着降低(从0.249 h -1 ; P <0.01),而吸收程度没有改变(89%)。这种药代动力学相互作用可以通过喹那普利在肠道水平上竞争性抑制头孢氨苄活性转运来解释。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号